Whereas slowly progressing patients without codon 816 mutations in KIT may respond well to imatinib or masitinib, this is usually not the case in SM patients in whom neoplastic cells display KIT D816V which confers resistance [54,55]. Here, KIT is linked to systemic mastocytosis.